Study of Favelizimab Coformulated With Pembrolizumab in Participants With Selected Solid Tumors
The purpose of this study is to evaluate pathological complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous